Success Metrics

Clinical Success Rate
92.7%

Based on 38 completed trials

Completion Rate
93%(38/41)
Active Trials
1(2%)
Results Posted
26%(10 trials)
Terminated
3(6%)

Phase Distribution

Ph not_applicable
2
4%
Ph phase_1
8
16%
Ph phase_3
1
2%
Ph early_phase_1
1
2%
Ph phase_2
14
28%

Phase Distribution

9

Early Stage

14

Mid Stage

1

Late Stage

Phase Distribution26 total trials
Early Phase 1First-in-human
1(3.8%)
Phase 1Safety & dosage
8(30.8%)
Phase 2Efficacy & side effects
14(53.8%)
Phase 3Large-scale testing
1(3.8%)
N/ANon-phased studies
2(7.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

90.5%

38 of 42 finished

Non-Completion Rate

9.5%

4 ended early

Currently Active

1

trials recruiting

Total Trials

50

all time

Status Distribution
Active(1)
Completed(38)
Terminated(4)
Other(7)

Detailed Status

Completed38
unknown7
Terminated3
Active, not recruiting1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
50
Active
1
Success Rate
92.7%
Most Advanced
Phase 3

Trials by Phase

Early Phase 11 (3.8%)
Phase 18 (30.8%)
Phase 214 (53.8%)
Phase 31 (3.8%)
N/A2 (7.7%)

Trials by Status

active_not_recruiting12%
terminated36%
unknown714%
withdrawn12%
completed3876%

Recent Activity

1 active trials
Showing 5 of 50
completedphase_2

CLL-Irl Study. CTRIAL-IE (ICORG) 07-01, V7

NCT00812669
completedphase_1

Melphalan and Radiation Therapy Followed By Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Stage I, Stage II, or Stage III Multiple Myeloma

NCT00112827
active_not_recruiting

Cytogenetic Studies in Acute Leukemia and Multiple Myeloma

NCT00048958
completedphase_1

Decitabine and Tretinoin in Treating Patients With Myelodysplastic Syndromes

NCT00382200
terminatedearly_phase_1

Oblimersen Sodium & Combination Chemotherapy in Treating Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma

NCT00736450
View all 50 trials

Clinical Trials (50)

Showing 20 of 50 trialsScroll for more
NCT00812669Phase 2

CLL-Irl Study. CTRIAL-IE (ICORG) 07-01, V7

Completed
NCT00112827Phase 1

Melphalan and Radiation Therapy Followed By Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Stage I, Stage II, or Stage III Multiple Myeloma

Completed
NCT00048958

Cytogenetic Studies in Acute Leukemia and Multiple Myeloma

Active Not Recruiting
NCT00382200Phase 1

Decitabine and Tretinoin in Treating Patients With Myelodysplastic Syndromes

Completed
NCT00736450Early Phase 1

Oblimersen Sodium & Combination Chemotherapy in Treating Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma

Terminated
NCT01004640

Study of Blood and Bone Marrow Samples in Patients With Chronic Myelogenous Leukemia Enrolled on a CALGB Clinical Trial

Unknown
NCT00816413Phase 1

Donor Stem Cell Transplant, Pentostatin, and Total-Body Irradiation in Treating Patients With Hematological Cancer

Withdrawn
NCT00769327Phase 2

Nilotinib and Imatinib Mesylate in Treating Patients With Early Chronic Phase Chronic Myelogenous Leukemia

Completed
NCT00792142Phase 2

Bortezomib, Thalidomide, and Dexamethasone After Melphalan and Stem Cell Transplant in Treating Patients With Stage I-III Multiple Myeloma

Completed
NCT04363190

Genomic Instability in Vascular Surgeons

Completed
NCT01165996Phase 1

Differentiation Therapy With Decitabine in Treating Patients With Myelodysplastic Syndrome

Completed
NCT01093586Phase 2

Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Completed
NCT02992860Phase 2

Single Agent JNJ-56022473 in MDS and AML Patients FAILING HYPOMETHYLATING AGENT BASED THERAPY

Terminated
NCT00425477Phase 2

Bexarotene and GM-CSF in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia

Completed
NCT00809211Phase 2

Nilotinib in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Completed
NCT00498953Phase 1

Combination Chemotherapy and Radiation Therapy With or Without Lapatinib in Treating Patients With Locally Advanced Cancer of the Larynx or Hypopharynx

Completed
NCT00445744Not Applicable

Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome

Completed
NCT00899795

Evaluating Cell Damage in Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, or Fanconi Anemia; in Patients Who Were Exposed to Alkylating Agents; and in Healthy Volunteers

Completed
NCT01505699

Biomarkers in Samples From Patients With B-Cell Acute Lymphoblastic Leukemia

Completed
NCT00899873

Biomarkers in Samples From Patients With Chronic Lymphocytic Leukemia Treated on Clinical Trial ECOG-2997

Completed

Drug Details

Intervention Type
GENETIC
Total Trials
50